In Q2 of 2025, LSI Alumni raised over $500 million across 50+ deals and two M&A transactions. Our quarterly Alumni Funding Report features transactions made by these medical device startups and their investors.
To view the full report with the deals, companies, and investors involved, sign up for a free Compass account here. Here’s a quick look at a few of the deals:
|
Company |
Amount |
Type/Stage |
|
OncoHost |
€2.5M |
Grant |
|
illumicell AI |
$2M |
Pre-Seed |
|
Azalea Vision |
€9M |
Series A |
|
Materna Medical |
$20M |
Series B2 |
|
Biolinq |
$100M |
Series C |
|
restor3d |
$38M |
Later Stage |
OncoHost and its European partners were awarded a €2.5 million EIC Transition grant to advance the development of NeutroFlow, a novel blood-based biomarker test for predicting immunotherapy response across five cancer types. The test aims to bring a cost-effective, point-of-care solution into routine clinical use, improving treatment precision and patient outcomes.
Investors included: EIC Transition Program of Horizon Europe
illumicell AI raised $2 million in pre-seed funding to accelerate development of its portable, real-time AI platform for male fertility diagnostics. By bringing lab-grade fluid analysis to the point of care, the startup aims to close diagnostic gaps, reduce delays, and expand access to cellular health insights.
Investors included: KOFA Healthcare, Harvard Phoenix Venture Fund, MedTechSyndicates, Dr. Jeremy Teoh, other healthcare operators, clinicians, and early-stage funds
Azalea Vision raised €9 million in the first closing of its €15 million Series A to accelerate development of its intelligent ocular health platform. The funding will support first-in-human clinical trials, FDA IDE approval efforts, and advancement toward commercialization.
Investors included: SPRIM Global Investments, Afrimobility, and an undisclosed strategic investor
Materna Medical announced the completion of a recent close within an ongoing $20 million Series B2 financing round to support development and FDA submission of Ellora™, a device designed to reduce pelvic floor injury during vaginal delivery. The funding will advance the company’s mission to transform the standard of care in labor and delivery across top U.S. hospitals.
Investors included: InnovaHealth Partners (led), GLIN Impact Capital, Wealthing VC Club, Citrine Angels, Wavemaker Three-Sixty Health, Kimera Limited, Women’s Venture Capital Fund, Golden Seeds
Biolinq announced a $100 million Series C round to advance its intradermal glucose sensor platform toward regulatory approval and commercial launch. The funding supports the company’s transition to market readiness, bringing its biowearable technology one step closer to empowering people with Type 2 diabetes (not on insulin) through real-time metabolic health insights.
Investors included: Alpha Wave Ventures (led), RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, Features Capital.
restor3d raised $38 million in growth capital to accelerate the commercialization of four new fully 3D printed orthopedic product lines and expand access to personalized musculoskeletal care. The funding will support continued innovation in AI-driven design and additive manufacturing as the company scales its platform across musculoskeletal reconstruction.
Investors included: Summers Value Partners, other existing and new investors
17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy